A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia

Trial Profile

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Idelalisib (Primary) ; Obinutuzumab (Primary) ; Tirabrutinib (Primary)
  • Indications Lymphoid leukaemia
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 08 Jun 2018 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.
    • 08 Jun 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.
    • 09 Nov 2017 Planned End Date changed from 1 Oct 2022 to 1 Aug 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top